Is benign prostatic obstruction surgery indicated for improving overactive bladder symptoms in men with lower urinary tract symptoms?

被引:8
|
作者
Cornu, Jean-Nicolas [1 ]
Grise, Philippe
机构
[1] Rouen Univ Hosp, Dept Urol, 1 Rue Germont, F-76031 Rouen 1, France
关键词
benign prostatic obstruction; lower urinary tract symptoms; overactive bladder; surgery; HOLMIUM LASER ENUCLEATION; DETRUSOR OVERACTIVITY; TRANSURETHRAL RESECTION; BETA(3)-ADRENOCEPTOR AGONIST; OUTLET OBSTRUCTION; DOUBLE-BLIND; MIRABEGRON; EFFICACY; PROSTATECTOMY; TOLERABILITY;
D O I
10.1097/MOU.0000000000000249
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of reviewLower urinary tract symptoms (LUTS) in men are highly prevalent, and include both storage and voiding symptoms in many cases. The effect of benign prostatic obstruction (BPO) relief on storage symptoms remains unclear.Recent findingsThe present review summarizes data about the relation between overactive bladder (OAB), voiding symptoms, and urodynamic characteristics in men with LUTS. Pathomechanisms of OAB in a context of BPO are reviewed. Rates of persistent bladder dysfunction after BPO relief are described along with predictive factors of persisting OAB.SummaryOAB is a common clinical feature in a population of male LUTS, often concomitant with voiding symptoms. Although detrusor overactivity is found in some patients with OAB and BPO, there is no absolute correspondence between clinical symptoms and urodynamic findings. In the context of BPO, OAB pathophysiology implicates nitric oxide pathway, bladder ischemia, ageing of the urinary tract, and calcium-activated potassium channels activity. BPO relief can be followed in the medium term by persistence of OAB symptoms, and preoperative detrusor overactivity has been identified as the main predictive factor. However, preoperative urodynamics remain only indicated in specific cases, when it could directly influence clinical decision-making. Antimuscarinics may be the treatment of choice for persistent symptoms after surgery, but there is no firm recommendation in this clinical setting.
引用
收藏
页码:17 / 21
页数:5
相关论文
共 50 条
  • [21] Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder - A randomized controlled trial
    Kaplan, Steven A.
    Roehrborn, Claus G.
    Rovner, Eric S.
    Carlsson, Martin
    Bavendam, Tamara
    Guan, Zhonghong
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (19): : 2319 - 2328
  • [22] Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
    Jung, Jae Hung
    Kim, Jiye
    MacDonald, Roderick
    Reddy, Balaji
    Kim, Myung Ha
    Dahm, Philipp
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (11):
  • [23] Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
    Gonzalez, Ricardo R.
    Kaplan, Steven A.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (04) : 609 - 617
  • [24] Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms
    Sarma, Aruna V.
    Wei, John T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (03) : 248 - 257
  • [25] Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement
    Mills, Ian W.
    Crossland, Anna
    Patel, Anup
    Ramonas, Henrikas
    EUROPEAN UROLOGY, 2007, 52 (02) : 503 - 509
  • [26] Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia
    Gregory R. Mullen
    Steven A. Kaplan
    Current Urology Reports, 2021, 22
  • [27] Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia
    Mullen, Gregory R.
    Kaplan, Steven A.
    CURRENT UROLOGY REPORTS, 2021, 22 (01)
  • [28] Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia
    Jung, Jae Hung
    McCutcheon, Karen Ann
    Borofsky, Michael
    Young, Shamar
    Golzarian, Jafar
    Reddy, Balaji
    Shin, Tae Young
    Ha Kim, Myung
    Narayan, Vikram
    Dahm, Philipp
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2020, (12):
  • [29] Beta 3 Adrenoreceptor Agonist for the Management of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia: A Systematic Review
    Kang, Tae Wook
    Kim, Su Jin
    Kim, Myung Ha
    Jung, Jae Hung
    INTERNATIONAL NEUROUROLOGY JOURNAL, 2021, 25 (03) : 182 - 191
  • [30] Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial
    Elbaz, Ramy
    El-Assmy, Ahmed
    Zahran, Mohamed H.
    Hashem, Abdelwahab
    Shokeir, Ahmed A.
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (05) : 390 - 396